Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1973 2
1974 1
1982 2
1983 2
1985 1
1986 1
1987 3
1988 2
1989 1
1990 1
1991 2
1992 4
1993 4
1994 6
1995 2
1996 1
1997 2
1998 1
1999 1
2000 1
2001 4
2002 2
2003 2
2005 1
2008 1
2009 2
2010 2
2011 1
2012 5
2013 2
2014 3
2015 3
2016 1
2017 2
2020 2
2021 1
2022 3
2023 4
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

79 results

Results by year

Filters applied: . Clear all
Page 1
Cancer cachexia.
Kern KA, Norton JA. Kern KA, et al. JPEN J Parenter Enteral Nutr. 1988 May-Jun;12(3):286-98. doi: 10.1177/0148607188012003286. JPEN J Parenter Enteral Nutr. 1988. PMID: 3292798 Review.
First-in-human, phase 1 study of PF-06753512, a vaccine-based immunotherapy regimen (VBIR), in non-metastatic hormone-sensitive biochemical recurrence and metastatic castration-resistant prostate cancer (mCRPC).
Autio KA, Higano CS, Nordquist L, Appleman LJ, Zhang T, Zhu XH, Babiker H, Vogelzang NJ, Prasad SM, Schweizer MT, Madan RA, Billotte S, Cavazos N, Bogg O, Li R, Chan K, Cho H, Kaneda M, Wang IM, Zheng J, Tang SY, Hollingsworth R, Kern KA, Petrylak DP. Autio KA, et al. Among authors: kern ka. J Immunother Cancer. 2023 Mar;11(3):e005702. doi: 10.1136/jitc-2022-005702. J Immunother Cancer. 2023. PMID: 36948505 Free PMC article. Clinical Trial.
A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer.
Curigliano G, Shapiro GI, Kristeleit RS, Abdul Razak AR, Leong S, Alsina M, Giordano A, Gelmon KA, Stringer-Reasor E, Vaishampayan UN, Middleton M, Olszanski AJ, Rugo HS, Kern KA, Pathan N, Perea R, Pierce KJ, Mutka SC, Wainberg ZA. Curigliano G, et al. Among authors: kern ka. Br J Cancer. 2023 Jan;128(1):30-41. doi: 10.1038/s41416-022-02025-9. Epub 2022 Nov 5. Br J Cancer. 2023. PMID: 36335217 Free PMC article. Clinical Trial.
79 results